Search
Leap Therapeutics Inc
LPTXAdd to Watchlist
2.050USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
68.57MMarket Cap
LossP/E TTM
More Details of Leap Therapeutics Inc Company
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Leap Therapeutics Inc Info
Ticker SymbolLPTX
Company nameCypherpunk Technologies Inc
IPO dateJan 24, 2017
CEOOnsi (Douglas E)
Number of employees52
Security typeOrdinary Share
Fiscal year-endJan 24
Address47 Thorndike Street
CityCAMBRIDGE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02142
Phone16172524343
Websitehttps://www.leaptx.com/
Ticker SymbolLPTX
IPO dateJan 24, 2017
CEOOnsi (Douglas E)
Company Executives of Leap Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
168.96K
+99.87%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
168.75K
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
168.75K
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
168.75K
--
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+0.50%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
132.51K
+82.07%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
168.96K
+99.87%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
168.75K
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
168.75K
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
168.75K
--
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+0.50%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
132.51K
+82.07%
FAQs
Who are the top five shareholders of Leap Therapeutics Inc?
The top five shareholders of Leap Therapeutics Inc are: Dr. James H. Cavanaugh, Ph.D.
How many institutions hold shares of Leap Therapeutics Inc (LPTX)?
As of 2026Q1, 114 institutions hold shares of Leap Therapeutics Inc, with a combined market value of approximately 11.73M, accounting for 12.01% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -9047212.00.